Open AccessP812: LONG‐TERM COMPLEMENT INHIBITION AND SURVIVAL OUTCOMES IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: AN INTERIM ANALYSIS OF THE RAVULIZUMAB CLINICAL TRIALS
Author(s) -
Kulasekararaj A.,
Brodsky R.,
Griffin M.,
Kulagin A.,
Ogawa M.,
Wang J.,
Mujeebuddin A.,
Nishimura J.I.,
Peffault de Latour R.,
Szer J.,
Lee J. W.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846132.33920.32
Subject(s) - paroxysmal nocturnal hemoglobinuria , eculizumab , medicine , clinical trial , dosing , adverse effect , hemoglobinuria , pediatrics , intensive care medicine , anemia , immunology , complement system , antibody